Rheonix to expand commercialization efforts, 12/15
December 2015—Rheonix raised $28.6 million to further expand the company’s commercialization efforts for its molecular testing platforms, the Encompass MDx and Encompass Optimum.
Webinars and Sponsored Roundtables — Register Now
Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
OGT licenses SNP probe technology, 12/15
December 2015—Oxford Gene Technology has entered into a deal with Baylor Miraca Genetics Laboratories, licensing the use of OGT’s proprietary single nucleotide polymorphism array probe technology.
Assay for measuring dabigatran, 12/15
December 2015—Diagnostica Stago launched its next-generation ecarin-based chromogenic assay for dabigatran, STA-ECA II. Fully automated with barcoded loading on Stago’s high throughput analyzers, STA-ECA II enables laboratories to measure dabigatran (Pradaxa) in plasma samples and is insensitive to lupus anticoagulants and heparin along with coagulation factor and fibrinogen levels.
BioTheranostics, Celsee Diagnostics collaboration, 12/15
December 2015—BioTheranostics announced a collaboration agreement with Celsee Diagnostics (formerly DeNovo Sciences) to investigate the technical feasibility of using BioTheranostics’ proprietary biomarkers in the development of blood-based diagnostics.
Genital swab claim cleared for HSV test, 11/15
November 2015—Quest Diagnostics announced that its Focus Diagnostics products business has received 510(k) clearance to add the genital swab claim to its Simplexa HSV 1 and 2 Direct molecular test on the 3M Integrated Cycler.
Urine-based prostate cancer test, 11/15
November 2015—MDxHealth announced the commercial launch of its noninvasive, urine-based test, SelectMDx for prostate cancer, in Europe via the company’s laboratory facilities in Nijmegen, the Netherlands.
Affymetrix, Luminex distribution agreement, 11/15
November 2015—Affymetrix and Luminex announced a distribution agreement under which eBioscience, a business unit of Affymetrix, will sell Luminex’s Magpix, Luminex 200, and Flexmap 3D multiplexed assay platforms in specified countries in the Americas, Asia, and Europe.
Cell culture chambers, 11/15
November 2015—Sarstedt introduced Lumox x-well cell culture chambers with a 50 µm ultrathin, gas-permeable film base that combines excellent imaging with superior cell growth. Compared with plastic or glass bases, the gas-permeable Lumox film provides more effective gas exchange and homogeneous cell growth.
Micropolymer IHC systems, 11/15
November 2015—Bio SB PolyDetector Systems are highly sensitive micropolymeric detection systems that allow for the demonstration of antigens in formalin-fixed, paraffin-embedded tissues, cryostat sections, blood smears, cytosmears, and cell preparations.
Whole exome sequencing solution, 11/15
November 2015—Roche has launched the SeqCap EZ Med-Exome Target Enrichment Kit, a comprehensive whole exome sequencing solution designed to increase the discovery and detection of human genetic variants associated with disease while reducing sequencing costs. For research use only; not for use in diagnostic procedures.